Mefloquine

Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research[1][2][3].

Product Specifications

CAS Number

[53230-10-7]

Product Name Alternative

Mefloquin

UNSPSC

12352005

Target

Autophagy; Parasite; Potassium Channel; ROS Kinase; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Protein Tyrosine Kinase/RTK

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mefloquine.html

Purity

99.96

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O[C@H]([C@]1([H])NCCCC1)C2=CC(C(F)(F)F)=NC3=C(C(F)(F)F)C=CC=C32

Molecular Formula

C17H16F6N2O

Molecular Weight

378.31

References & Citations

[1]Kang J, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK andHERG. J Pharmacol Exp Ther. 2001 Oct;299 (1) :290-6.|[2]Yan KH, et al. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncol Lett. 2013 May;5 (5) :1541-1545.|[3]Kaho Shionoya, et al. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021 Apr 30;12:651403.|[4]Rafael Pacheco-Costa, et al. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 Sep;114:22-31.